Oppenheimer lowered the firm’s price target on Nurix Therapeutics (NRIX) to $30 from $32 and keeps an Outperform rating on the shares following quarterly results. Oppenheimer says it is “getting a bit tired” of the myopic argument that the CLL market is a zero-sum game – with BeOne beating Nurix to the punch. By the firm’s estimates, NX-5948 is 6-12 months behind BeOne, but has advantages in safety and efficacy that can be exploited.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics price target lowered to $16 from $17 at Morgan Stanley
- Buy Rating for Nurix Therapeutics Driven by Strong Financials and Upcoming Clinical Milestones
- Nurix Therapeutics price target lowered to $34 from $36 at H.C. Wainwright
- Top 3 Trending Stocks, According to Analysts – 7/11/2025
- Optimistic Buy Rating for Nurix Therapeutics Amid Regulatory and Strategic Catalysts